Insider Selling: CeriBell (NASDAQ:CBLL) VP Sells 569 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 569 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $19.79, for a total value of $11,260.51. Following the sale, the vice president owned 18,331 shares of the company’s stock, valued at $362,770.49. The trade was a 3.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

David Foehr also recently made the following trade(s):

• On Tuesday, February 24th, David Foehr sold 781 shares of CeriBell stock. The shares were sold at an average price of $19.98, for a total transaction of $15,604.38.
• On Tuesday, February 3rd, David Foehr sold 5,556 shares of CeriBell stock. The shares were sold at an average price of $20.00, for a total transaction of $111,120.00.
• On Monday, January 5th, David Foehr sold 5,556 shares of CeriBell stock. The stock was sold at an average price of $22.60, for a total value of $125,565.60.
• On Wednesday, December 3rd, David Foehr sold 5,265 shares of CeriBell stock. The stock was sold at an average price of $16.83, for a total value of $88,609.95.

CeriBell Stock Down 4.8%

NASDAQ:CBLL traded down $0.95 during trading hours on Wednesday, hitting $18.95. The stock had a trading volume of 713,550 shares, compared to its average volume of 351,326. The company has a market cap of $703.05 million, a PE ratio of -12.55 and a beta of 1.03. The business has a 50 day simple moving average of $21.26 and a two-hundred day simple moving average of $16.17. CeriBell, Inc. has a 1-year low of $10.01 and a 1-year high of $25.98. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The business had revenue of $24.78 million for the quarter, compared to analysts’ expectations of $23.95 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. Analysts predict that CeriBell, Inc. will post -2.46 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently commented on the company. BTIG Research reiterated a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research note on Wednesday, January 28th. TD Cowen restated a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. Canaccord Genuity Group increased their target price on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, JPMorgan Chase & Co. decreased their price target on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Peregrine Capital Management LLC acquired a new position in shares of CeriBell in the 2nd quarter worth approximately $6,399,000. Emerald Advisers LLC lifted its stake in CeriBell by 3.9% during the second quarter. Emerald Advisers LLC now owns 125,869 shares of the company’s stock worth $2,358,000 after purchasing an additional 4,727 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its holdings in CeriBell by 26.1% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 98,185 shares of the company’s stock worth $1,839,000 after purchasing an additional 20,350 shares during the period. TimesSquare Capital Management LLC increased its stake in CeriBell by 48.5% during the second quarter. TimesSquare Capital Management LLC now owns 796,945 shares of the company’s stock valued at $14,927,000 after purchasing an additional 260,116 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of CeriBell by 55.4% during the second quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock worth $8,391,000 after purchasing an additional 159,698 shares during the period.

Key CeriBell News

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 beat on both EPS and revenue — CeriBell reported a loss of ($0.36) vs. consensus ($0.43) and revenue of $24.78M vs. $23.95M expectations, showing top‑line strength and a smaller-than-expected loss. Zacks: Q4 results
• Positive Sentiment: Management highlighted market expansion and revenue acceleration on the earnings call, which supports ongoing growth expectations for newborn hearing-screening adoption. Earnings call transcript
• Neutral Sentiment: FY2026 revenue guidance of $111.0M–$115.0M was issued, roughly in line with the Street estimate (~$112.7M) — guidance supports growth but isn’t a clear upside surprise. (Press release/earnings coverage.)
• Neutral Sentiment: Balance-sheet strength: very high current and quick ratios indicate ample liquidity, reducing short-term financing risk. (See filings/coverage.)
• Negative Sentiment: Insider selling: Director Josef Parvizi sold 16,714 shares (recently continued a pattern of sales), which can be viewed negatively by some investors. Insider selling report
• Negative Sentiment: Company remains unprofitable with a negative net margin (~‑63%), negative ROE, and an expected full‑year EPS loss — profitability timeline remains a key risk for valuation. Business Insider: results summary
• Negative Sentiment: Mixed analyst moves — at least one price-target cut alongside continued buy ratings elsewhere creates divergent expectations that can increase volatility. (Analyst coverage summarized in public filings/press coverage.)

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.